Ezra Cohen to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Ezra Cohen has written about Programmed Cell Death 1 Receptor.
Connection Strength
1.371
-
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017 09 21; 2(18).
Score: 0.538
-
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 06; 22(6):883-892.
Score: 0.173
-
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
Score: 0.172
-
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. Clin Cancer Res. 2020 07 01; 26(13):3345-3359.
Score: 0.160
-
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491.
Score: 0.149
-
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jan 01; 10(1):32-41.
Score: 0.052
-
Eganelisib, a First-in-Class PI3K? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 06 13; 29(12):2210-2219.
Score: 0.050
-
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 01; 28(5):903-914.
Score: 0.046
-
PI3K? is a molecular switch that controls immune suppression. Nature. 2016 11 17; 539(7629):437-442.
Score: 0.031